Investor Presentaiton
SELECT TRIALS - INSULIN EFSITORA ALFA
Study
Indication*
NCT05462756
Type 2
Diabetes
NCT05275400
Type 2
Diabetes
NCT05662332
Type 2
Diabetes
NCT05463744
Type 1
Diabetes
Title
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly
Basal Insulin Compared to Insulin Glargine in Adult
Participants With Type 2 Diabetes on Multiple Daily
Injections (QWINT-4)
A Study of Insulin Efsitora Alfa (LY3209590) Compared With
Insulin Degludec in Participants With Type 2 Diabetes
Currently Treated With Basal Insulin (QWINT-3)
A Study of Insulin Efsitora Alfa (LY3209590) Compared to
Glargine in Adult Participants With Type 2 Diabetes Who
Are Starting Basal Insulin for the First Time (QWINT-1)
A Study of Insulin Efsitora Alfa (LY3209590) Compared With
Insulin Degludec in Participants With Type 1 Diabetes
Treated With Multiple Daily Injection Therapy (QWINT-5)
A Study of Insulin Efsitora Alfa (LY3209590) Compared to
NCT05362058 Diabetes Degludec in Adults With Type 2 Diabetes Who Are Starting
Basal Insulin for the First Time (QWINT-2)
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
Phase Patients
Primary Outcome*
**
Lilly
Primary
Completion
Completion
3
730
Change from Baseline in Hemoglobin A1c (HbA1c)
Mar 2024
Mar 2024
3
986
Change from Baseline in Hemoglobin A1c (HbA1c)
May 2024 May 2024
3
796
Change from Baseline in Hemoglobin A1c (HbA1c)
Jul 2024
Jul 2024
3
692
Change from Baseline in Hemoglobin A1c (HbA1c)
May 2024
May 2024
3
912
Change from Baseline in Hemoglobin A1c (HbA1c)
Apr 2024
Apr 2024
Source: clinicaltrials.gov, July 13, 2023
2023 Q2 EARNINGS
37View entire presentation